izpis_h1_title_alt

2023 global inventory of commercial molecular tests for human papillomaviruses (HPV)
ID Poljak, Mario (Author), ID Oštrbenk Valenčak, Anja (Author), ID Cuschieri, Kate S. (Author), ID Bohinc, Klara (Author), ID Arbyn, Marc (Author)

.pdfPDF - Presentation file, Download (1,87 MB)
MD5: 621D4791137E0ED78D4C4D8D63D46F67
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S1386653224000337 This link opens in a new window

Abstract
To suit the needs of the human papillomaviruses (HPV) community comprehensively, a range of commercial HPV tests with different performance characteristics are required. Four periodic inventories of commercial HPV molecular tests present in the global market were published previously in 2010, 2012, 2015 and 2020. For the fifth inventory, data were retrieved from internal files and a detailed search using the main bibliographic databases as well as general internet search without period or language restrictions was performed in December 2023. At least 264 distinct HPV tests (and 511 test variants) were available globally in December 2023. A small 2020–2023 net increase in total numbers was observed, but with a strong introduction/withdrawal dynamic: 86 new distinct HPV tests (and 141 variants) were introduced and 76 tests (and 55 variants) were withdrawn from the market in the last four years. Although quality improvement of some tests was recorded, half of all HPV tests are still without a single peer-reviewed publication, and 79 % of tests are without published evidence that demonstrate performance characteristics are in line with requirements agreed in the HPV community. Only a relatively small pool of tests fulfill the operational/performance characteristics required to meet the global cervical cancer screening challenge. Although clinical and analytical performance characteristics of many commercial HPV tests are largely unknown, such tests are used worldwide in daily clinical practice and research, with potentially deleterious consequences. Due to this long-lasting unfavorable situation, significant scope for improvement persists for both manufacturers of HPV tests and the HPV community.

Language:English
Keywords:cervical cancer, HPV, human papillomaviruses, screening, test
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:8 str.
Numbering:Vol. 172, art. 105671
PID:20.500.12556/RUL-156261 This link opens in a new window
UDC:618.1
ISSN on article:1873-5967
DOI:10.1016/j.jcv.2024.105671 This link opens in a new window
COBISS.SI-ID:195047171 This link opens in a new window
Publication date in RUL:16.05.2024
Views:88
Downloads:410
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of clinical virology
Publisher:Elsevier, Pan American Society for Clinical Virology, European Society for Clinical Virology
ISSN:1873-5967
COBISS.SI-ID:23214341 This link opens in a new window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Secondary language

Language:Slovenian
Keywords:rak materničnega vratu, HPV, humani papiloma virusi, presejanje, test

Projects

Funder:EC - European Commission
Funding programme:H2020
Project number:847845
Name:Risk-based screening for cervical cancer
Acronym:RISCC

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0083
Name:Odnosi parazitskega obstajanja

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back